×
TNF Pharmaceuticals EBITDA 2012-2024 | TNFA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TNF Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
TNF Pharmaceuticals EBITDA 2012-2024 | TNFA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TNF Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$86.6B
Takeda Pharmaceutical (TAK)
$46.8B
Merck (MKGAF)
$24.9B
Summit Therapeutics (SMMT)
$23.1B
Astellas Pharma (ALPMY)
$21.7B
Sandoz Group AG (SDZNY)
$17.9B
United Therapeutics (UTHR)
$15.1B
Shionogi (SGIOY)
$13.2B
Neurocrine Biosciences (NBIX)
$12.3B
Catalent (CTLT)
$10.8B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.7B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4B
Dyne Therapeutics (DYN)
$3.4B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Centessa Pharmaceuticals (CNTA)
$1.9B
Recursion Pharmaceuticals (RXRX)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.6B
Ardelyx (ARDX)
$1.5B
NewAmsterdam Pharma (NAMS)
$1.4B